Want to see IL:NRGN full AI Analyst Report?
Top Page
Nrgene
(TASE:NRGN)
Select Model
Select Model
Rating:47Neutral
Price Target:
86.00
▼(-38.26% Downside)
Action:Reiterated
Date:09/29/26
The score is held back primarily by very weak technicals (price far below all major moving averages, negative MACD, and extremely low RSI). Financial performance shows a meaningful 2025 rebound in revenue, gross margin, and cash flow, but the company remains deeply loss-making and free cash flow is still modest and volatile. Valuation is constrained by negative earnings (negative P/E) and lack of a stated dividend yield.
Positive Factors
Revenue and gross-margin rebound
The sharp 2025 revenue rebound and major gross-margin improvement indicate stronger commercial activity and better unit economics. If maintained, this combination can expand the contribution from the company’s software and genomics services, supporting reinvestment and improving operating leverage over the next several quarters.
Negative Factors
Persistent operating losses
Nrgene’s improved revenue and gross margin have not yet translated into sustainable profitability. Deeply negative EBIT and net margins indicate that operating expenses still exceed gross profit by a substantial amount, leaving the business vulnerable if growth moderates and limiting internally funded investment.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and gross-margin rebound
The sharp 2025 revenue rebound and major gross-margin improvement indicate stronger commercial activity and better unit economics. If maintained, this combination can expand the contribution from the company’s software and genomics services, supporting reinvestment and improving operating leverage over the next several quarters.
Read all positive factors
Nrgene (NRGN) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪11.06M
Dividend YieldN/A
Average Volume (3M)8.84K
Price to Earnings (P/E)―
Beta (1Y)0.65
Revenue Growth115.63%
EPS Growth60.19%
CountryIL
Employees23
SectorGeneral
Sector StrengthN/A
IndustrySoftware - Application
Share Statistics
EPS (TTM)N/A
Shares Outstanding13,327,785
10 Day Avg. Volume11,756
30 Day Avg. Volume8,843
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.94
Price to Sales (P/S)2.64
P/FCF Ratio116.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nrgene Business Overview & Revenue Model
Company Description
NRGene Technologies Ltd is an AI-powered genomics firm that designs sophisticated computational tools and advanced algorithms, serving clients globally across North America, Europe, the Middle East, Africa, and Asia Pacific. The company provides s...
How the Company Makes Money
Nrgene’s monetization is centered on providing access to its bioinformatics/genomics software and related services to customers that need genomic assembly and analysis capabilities. Key revenue streams typically include (1) software licensing/subs...
Nrgene Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
63
Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.25M | 3.17M | 1.29M | 2.00M | 3.16M | 4.46M |
| Gross Profit | 1.92M | 1.92M | 267.00K | 901.00K | 1.71M | 2.46M |
| EBITDA | -1.98M | -965.00K | -2.69M | -4.53M | -5.59M | -8.37M |
| Net Income | -2.58M | -1.50M | -3.36M | -5.24M | -6.21M | -8.34M |
Balance Sheet | ||||||
| Total Assets | 7.12M | 9.54M | 6.00M | 10.79M | 17.30M | 26.36M |
| Cash, Cash Equivalents and Short-Term Investments | 3.18M | 5.30M | 1.37M | 6.45M | 12.28M | 22.87M |
| Total Debt | 145.02K | 181.00K | 288.00K | 797.00K | 1.61M | 3.34M |
| Total Liabilities | 4.66M | 5.13M | 2.00M | 3.57M | 5.04M | 8.68M |
| Stockholders Equity | 2.51M | 4.31M | 3.96M | 7.21M | 12.26M | 17.68M |
Cash Flow | ||||||
| Free Cash Flow | -511.43K | 72.00K | -5.19M | -5.58M | -7.83M | -6.67M |
| Operating Cash Flow | 268.11K | 855.00K | -3.56M | -3.91M | -6.12M | -5.57M |
| Investing Cash Flow | 364.72K | 455.00K | -1.30M | -1.27M | 12.47M | -14.83M |
| Financing Cash Flow | 42.23K | 1.53M | -317.00K | -410.00K | -2.46M | 27.59M |
Nrgene Technical Analysis
Negative
139.30
Price Trends
149.77
Negative
186.35
Negative
216.84
Negative
Market Momentum
-18.66
Positive
7.83
Positive
28.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NRGN, the sentiment is Negative. The current price of 139.3 is above the 20-day moving average (MA) of 104.77, below the 50-day MA of 149.77, and below the 200-day MA of 216.84, indicating a bearish trend. The MACD of -18.66 indicates Positive momentum. The RSI at 7.83 is Positive, neither overbought nor oversold. The STOCH value of 28.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:NRGN.
Nrgene Peers Comparison
UnderperformOutperform
Sector (55)
IL:NRGN
Nrgene
83.00
-176.00
-67.95%
IL:MTRX
Matrix
10,210.00
-1,313.11
-11.40%
IL:TECT
Tectona
182.90
-162.30
-47.02%
IL:MPRS
Mediprss Pu
55.90
10.30
22.59%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.